Furthermore, our group previously provided the first evidence for N-terminally cleaved antagonistic CXCL10 in malignant high-grade serous ovarian tumour samples but not benign ovarian disease and suggested that this was responsible for reduced lymphocyte infiltration in these tumours [35]. This evidence concerns the gene CXCL10 and neoplasm.